Top Markets
Coin of the day
Quantum Genomics S.A. Quantum Genomics S.A.

Quantum Genomics S.A.

ALQGC
株式のランク #37063
Quantum Genomics S.A., a biopharmaceutical firm established in Paris, France,... Quantum Genomics S.A., a biopharmaceutical firm established in Paris, France, in 2005, focuses on creating treatments for cardiovascular ailments. Its therapeutic approach utilizes the brain aminopeptidase A inhibition (BAPAI) platform, primarily addressing high blood pressure (hypertension) and heart failure. The company's key asset, firibastat, is currently undergoing a crucial Phase III study as a standalone therapy for hypertension and is also in clinical trials for heart failure. Additionally, Quantum Genomics is progressing QGC011 for hypertension in combination therapy, and further developing QGC006 and QGC606 to target both hypertension and heart failure.
株価
$0.07600875
最終同期: 2024-11-20
時価総額
$2.06M
変化(1日)
-0.51%
変化(1年)
0.00%
FR
取引 Quantum Genomics S.A. (ALQGC)

カテゴリー

Quantum Genomics S.A.(ALQGC)の収益
Dec 2024 時点の収益 TTM: $2.14K
Quantum Genomics S.A. の最新の財務報告によると、現在の収益 (TTM) は $2.14K です。2023 年には $21.88K の収益があり、これは 2022 年の $2.70M と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Quantum Genomics S.A. の収益履歴(2009 ~ 2026)
各年末の収益
収益 変化
2026 (TTM) $2.14K 20,481.43%
2024 $10.41 -99.95%
2023 $21.88K -99.19%
2022 $2.70M -24.40%
2021 $3.57M 60.20%
2020 $2.23M 28.33%
2019 $1.74M 40,877.53%
2018 $4.24K 0.00%
2017 0.00 0.00%
2016 0.00 -100.00%
2015 $156.51K -60.11%
2014 $392.39K 1,539.89%
2013 $23.93K -5.52%
2012 $25.33K 1.90%
2011 $24.85K -3.18%
2010 $25.67K -6.76%
2009 $27.53K 0.00%
同業他社の収益
企業 収益 収益の差
$12.62B 589,224,844.91%
US
$6.02B 281,036,684.84%
NL
- -
CH
- -
KR
$10.11B 471,909,450.14%
BE